Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain

  1. Botana López, M.
  2. Camafort Babkowski, M.
  3. Campuzano Ruiz, R.
  4. Cebrián Cuenca, A.
  5. Gargallo Fernández, M.
  6. David de Paz, H.
  7. Redondo-Antón, J.
  8. Artime, E.
  9. Díaz-Cerezo, S.
  10. Rubio de Santos, M.
Revista:
Advances in Therapy

ISSN: 1865-8652,  0741-238X

Ano de publicación: 2024

Tipo: Artigo

DOI: 10.1007/S12325-024-02938-2 GOOGLE SCHOLAR lock_openAcceso aberto editor
Fonte de datos: Scopus